A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial. - 2025
A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial.
Bihlet, Asger Reinstrup; Henrotin, Yves; Lau, Edith Ming Chuet al.
Clonidine; Hyaluronic acid; Inflammation; Knee osteoarthritis; Randomized controlled trials; Viscosupplement; Rheumatology; Biomedical Engineering; Orthopedics and Sports Medicine
Abstract :
[en] [en] OBJECTIVES: Intra-articular treatments for osteoarthritis (OA) are limited by their efficacy, safety, or duration of response. JTA-004 is a potential novel treatment for OA for intra-articular (IA) injection, combining hyaluronic acid (HA) and clonidine with human plasma to enhance the effects of HA. The objectives of the trial were to evaluate the efficacy and safety of JTA-004 in participants with symptomatic knee OA, where the primary objective was evaluating the efficacy of JTA-004 in terms of WOMAC pain, compared to placebo.
DESIGN: The trial was a multicenter, Phase 3, randomized, double-blind, placebo- and active-controlled clinical trial, evaluating the efficacy and safety of a single IA injection of JTA-004, compared to saline (primary hypothesis) and an HA-comparator (Synvisc-One®) (secondary hypothesis) in knee OA with a Kellgren-Lawrence grade of 2 or 3. For the secondary hypothesis, non-inferiority of JTA-004 to active comparator by comparing the 2 treatment groups on the mean differences in WOMAC pain with a non-inferiority margin of Δ = 10 mm. Primary efficacy endpoint was the change from baseline in WOMAC pain to Month 3. The main secondary efficacy endpoints included changes from baseline in WOMAC function and stiffness at Months 3 and 6, OMERACT-OARSI responder rates, global assessments, and use of rescue medication. Safety assessments were based on adverse events (AE) reporting, and post-injection vital signs.
RESULTS: A total of 746 participants were randomized, of which 687 (92.1%) completed the trial. The results indicated no significant differences in the primary endpoint between JTA-004 and placebo (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) nor in either of the efficacy outcomes of the main study population. The safety and tolerability of JTA-004 was good, and there were no differences in the frequency of any of the reported AEs or trial discontinuations between the study groups.
CONCLUSIONS: A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA symptoms in the overall study population.
Henrotin, Yves ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > Pathologie générale et physiopathologie - Techniques particulières de kinésithérapie
Lau, Edith Ming Chu ; Hong Kong Center for Clinical Research, Hong Kong. Electronic address: edith.lau@hkccr.co
Rieger, François ; Medsenic, Strasbourg, France. Electronic address: rieger.meds@gmail.com
Nicco, Carole ; Université Paris Cité, Paris, France, Medsenic, Strasbourg, France. Electronic address: carole.nicco@u-paris.fr
Language :
English
Title :
A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial.
McAlindon, T.E., LaValley, M.P., Harvey, W.F., et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis a randomized clinical trial. JAMA J. Am. Med. Assoc. 317:19 (2017), 1967–1975, 10.1001/jama.2017.5283.
Lo, G.H., Lavalley, M., Mcalindon, T., Felson, D.T., Intra-articular Hyaluronic Acid in Treatment of Knee Osteoarthritis., 290(23), 2012, 3115–3121.
Altman, R.D., Manjoo, A., Fierlinger, A., Niazi, F., Nicholls, M., The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet. Disord., 16(1), 2015, 10.1186/S12891-015-0775-Z.
Lo, G.H., LaValley, M., McAlindon, T., Felson, D.T., Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290:23 (2003), 3115–3121, 10.1001/JAMA.290.23.3115.
Rinaudo, M., Rheological investigation on hyaluronan-fibrinogen interaction. Int. J. Biol. Macromol. 43:5 (2008), 444–450, 10.1016/J.IJBIOMAC.2008.08.009.
Oates, K.M.N., Krause, W.E., Jones, R.L., Colby, R.H., Rheopexy of synovial fluid and protein aggregation. J. R. Soc. Interface 3:6 (2006), 167–174, 10.1098/RSIF.2005.0086.
Oates, K.M.N., Krause, W.E., Colby, R.H., Using rheology to probe the mechanism of joint lubrication: Polyelectrolyte/protein interactions in synovial fluid. Mater. Res. Soc. Symp Proc. 711 (2002), 53–58.
Xu, S., Yamanaka, J., Sato, S., Miyama, I., Yonese, M., Characteristics of complexes composed of sodium hyaluronate and bovine serum albumin. Chem. Pharm. Bull. 48:6 (2000), 779–783, 10.1248/CPB.48.779.
Nooh, M.H., Alshehri, M.S., Alzahrani, Z.S., et al. The efficacy and safety of intra-articular low molecular weight fraction of human serum albumin for the management of moderate to moderately severe knee osteoarthritis: a systematic review and meta-analysis. Cureus, 15(6), 2023, 10.7759/CUREUS.41240.
Bennell, K.L., Paterson, K.L., Metcalf, B.R., et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA J. Am. Med. Assoc. 326:20 (2021), 2021–2030, 10.1001/JAMA.2021.19415.
Katta, J., Jin, Z., Ingham, E., Fisher, J., Biotribology of articular cartilage–a review of the recent advances. Med Eng. Phys. 30:10 (2008), 1349–1363, 10.1016/J.MEDENGPHY.2008.09.004.
Zhang, Z., Barman, S., Christopher, G.F., The role of protein content on the steady and oscillatory shear rheology of model synovial fluids. Soft Matter 10:32 (2014), 5965–5973, 10.1039/C4SM00716F.
Park, J.Y., Duong, C.T., Sharma, A.R., et al. Effects of hyaluronic acid and γ-globulin concentrations on the frictional response of human osteoarthritic articular cartilage. PLoS One, 9(11), 2014, 10.1371/JOURNAL.PONE.0112684.
Cogan, C.J., Knesek, M., Tjong, V.K., et al. Assessment of intraoperative intra-articular morphine and clonidine injection in the acute postoperative period after hip arthroscopy. Orthop. J. Sports Med., 4(2), 2016, 10.1177/2325967116631335.
Buerkle, H., Huge, V., Wolfgart, M., et al. Intra-articular clonidine analgesia after knee arthroscopy. Eur. J. Anaesthesiol. 17:5 (2000), 295–299, 10.1046/J.1365-2346.2000.00659.X.
Gentili, M., Juhel, A., Bonnet, F., Peripheral analgesic effect of intra-articular clonidine. Pain 64:3 (1996), 593–596, 10.1016/0304-3959(95)00188-3.
Bettonville, M., Léon, M., Margaux, J., et al. Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study. BMC Musculoskelet. Disord., 22(1), 2021, 10.1186/S12891-021-04750-3.
Altman, R., Asch, E., Bloch, D., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum., 29, 1986.
Berenbaum, F., Blanco, F.J., Guermazi, A., et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis. 79:6 (2020), 800–810, 10.1136/annrheumdis-2019-216296.
Schnitzer, T.J., Easton, R., Pang, S., et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA J. Am. Med. Assoc., 2019, 10.1001/jama.2019.8044.
Schnitzer, T.J., Chevalier, X., Rovsing, H., et al. Intra-articular MM-II for the treatment of knee osteoarthritis pain: Efficacy and safety results from a 26-week, phase 2b, placebo-controlled, double-blind, randomized dose-ranging trial. Osteoarthr. Cartil., 2025, 10.1016/j.joca.2025.04.006.
Pham, T., van der Heijde, D., Altman, R.D., et al. OMERACT-OARSI initiative: Osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr. Cartil. 12:5 (2004), 389–399, 10.1016/j.joca.2004.02.001.
Angelini, F., Widera, P., Mobasheri, A., et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann. Rheum. Dis. 81:5 (2022), 666–675, 10.1136/annrheumdis-2021-221763.
Schieker, M., Conaghan, P.G., Mindeholm, L., et al. Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement: Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Intern. Med. 173:7 (2020), 509–515, 10.7326/M20-0527.
Bay-Jensen, A.C., Bihlet, A., Byrjalsen, I., et al. Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis. Sci. Rep., 11(1), 2021, 10.1038/S41598-021-86064-X.
van der Weegen, W., Wullems, J.A., Bos, E., Noten, H., van Drumpt, R.A.M., No difference between intra-articular injection of hyaluronic acid and placebo for mild to moderate knee osteoarthritis: a randomized, controlled, double-blind trial. J. Arthroplast. 30:5 (2015), 754–757, 10.1016/J.ARTH.2014.12.012.
Gregori, D., Giacovelli, G., Minto, C., et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA J. Am. Med. Assoc. 320 (2018), 2564–2579, 10.1001/jama.2018.19319.
Neogi, T., Colloca, L., Placebo effects in osteoarthritis: implications for treatment and drug development. Nat. Rev. Rheumatol. 19:10 (2023), 613–626, 10.1038/S41584-023-01021-4.
Zhang, W., Robertson, J., Jones, A.C., Dieppe, P.A., Doherty, M., The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 67:12 (2008), 1716–1723, 10.1136/ard.2008.092015.
Bannuru, R.R., McAlindon, T.E., Sullivan, M.C., Wong, J.B., Kent, D.M., Schmid, C.H., Effectiveness and implications of alternative placebo treatments: A systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163:5 (2015), 365–392, 10.7326/M15-0623.
Tuttle, A.H., Tohyama, S., Ramsay, T., et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 156:12 (2015), 2616–2626, 10.1097/j.pain.0000000000000333.
Bechman, K., Yates, M., Norton, S., Cope, A.P., Galloway, J.B., Placebo response in rheumatoid arthritis clinical trials. J. Rheumatol. 47:1 (2020), 28–34, 10.3899/JRHEUM.190008.
Wen, X., Luo, J., Mai, Y., et al. Placebo response to oral administration in osteoarthritis clinical trials and its associated factors: a model-based meta-analysis. JAMA Netw. Open, 5(10), 2022, E2235060, 10.1001/JAMANETWORKOPEN.2022.35060.
Dinç, M., Cevdet Soydemir, Ö., Exploring the efficacy of joint lavage in knee osteoarthritis: a focus on cytokines, degrading enzymes, and oxidative stress. Cartilage, 2024, 10.1177/19476035241304526.
Li, S., Jiang, X., Wang, J., et al. Clinical efficacy of 2-needle joint lavage for osteoarthritis-related knee pain and predictors of response based on knee mri osteoarthritis knee score: a medical records review study. J. Clin. Rheumatol. 29:8 (2023), 396–401, 10.1097/RHU.0000000000002029.
Tambiah, J.R.S., Simsek, I., Swearingen, C.J., et al. Comparing patient-reported outcomes from sham and saline-based placebo injections for knee osteoarthritis: data from a randomized clinical trial of lorecivivint. Am. J. Sports Med. 50:3 (2022), 630–636, 10.1177/03635465211067201.
Zhang, W., The powerful placebo effect in osteoarthritis. Clin. Exp. Rheumatol. 37:5 (2019), 118–123 Accessed January 2, 2025. 〈https://www.clinexprheumatol.org/abstract.asp?a=14758〉.
Sun, R., Zhao, W., Hao, Q., et al. Intra-articular clonidine for post-operative analgesia following arthroscopic knee surgery: a systematic review and meta-analysis. Knee Surg. Sports Trauma. Arthrosc. 22:9 (2014), 2076–2084, 10.1007/S00167-013-2615-8.
Bihlet, A.R., Byrjalsen, I., Andersen, J.R., et al. Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial. Clin. Exp. Rheuma 40:5 (2022), 1034–1037, 10.55563/clinexprheumatol/1kvgte.
Yazici, Y., McAlindon, T.E., Gibofsky, A., et al. Lorecivivint, a novel intraarticular CDC-like Kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1a inhibitor and wnt pathway modulator for the treatment of knee osteoarthritis: a Phase II randomized trial. Arthritis Rheumatol. 72:10 (2020), 1694–1706, 10.1002/art.41315.
Hirsch, G., O'Neill, T.W., Kitas, G., Sinha, A., Klocke, R., Accuracy of injection and short-term pain relief following intra-articular corticosteroid injection in knee osteoarthritis - an observational study. BMC Musculoskelet. Disord., 18(1), 2017, 10.1186/S12891-017-1401-Z.
Wu, T., Dong, Y., Song, H. xin, Fu, Y., Li, J. hua, Ultrasound-guided versus landmark in knee arthrocentesis: A systematic review. Semin Arthritis Rheum. 45:5 (2016), 627–632, 10.1016/j.semarthrit.2015.10.011.
Raynauld, J.P., Goldsmith, C.H., Bellamy, N., et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthr. Cartil. 13:2 (2005), 111–119, 10.1016/J.JOCA.2004.10.018.
Larghi, M.M., Grassi, M., Faugno, L., Placenza, E., Rampulla, C., Manzotti, A., Clinical outcome before and after COVID-19 quarantine in patients affect of knee and hip osteoarthritis. Acta Biomed. 91:4 (2020), 1–7, 10.23750/ABM.V91I4.10275.
Endstrasser, F., Braito, M., Linser, M., Spicher, A., Wagner, M., Brunner, A., The negative impact of the COVID-19 lockdown on pain and physical function in patients with end-stage hip or knee osteoarthritis. Knee Surg. Sports Trauma. Arthrosc. 28:8 (2020), 2435–2443, 10.1007/S00167-020-06104-3.
